Captopril

Product Overview

Captopril was the first orally active angiotensin-converting enzyme (ACE) inhibitor and represents one of the most remarkable stories in drug discovery history. Its origin traces to the 1960s, when Brazilian pharmacologist Sergio Ferreira isolated a peptide from the venom of the Brazilian pit viper Bothrops jararaca that potentiated bradykinin and lowered blood pressure. This peptide, teprotide, was shown by John Vane's group to inhibit ACE. The key breakthrough came at the Squibb Institute (now Bristol-Myers Squibb) where scientists Miguel Ondetti and David Cushman modeled the ACE active site on carboxypeptidase A and designed captopril to chelate the zinc cofactor via a sulfhydryl (-SH) group while occupying critical enzyme pockets. FDA approved captopril in 1981 under the brand name Capoten — launching an entirely new class of cardiovascular drugs that would go on to save millions of lives.

Captopril's mechanism is elegantly simple: it inhibits ACE, blocking the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. This produces vasodilation, reduced aldosterone secretion (decreased sodium and water retention), and increased bradykinin levels (additional vasodilation). The net effect is afterload reduction, decreased blood pressure, and improved cardiac output in heart failure. The sulfhydryl group that binds the zinc cofactor in ACE is essential for captopril's potency but also responsible for its unique side effects: a characteristic taste disturbance (dysgeusia) and skin rash, which are less common with later ACE inhibitors that lack the free -SH group.

Captopril differs from later ACE inhibitors (enalapril, lisinopril, ramipril) in that it is not a prodrug — it is active as administered and has a rapid onset of 15-30 minutes, making it suitable for hypertensive emergencies where oral treatment is appropriate. This fast onset also allows captopril to be used diagnostically in renal artery stenosis evaluation (captopril renography). The drug's thiol group also confers potential antioxidant properties, a feature absent from the dicarboxylate-containing ACE inhibitors that followed.

Although newer once-daily ACE inhibitors and ARBs have largely replaced captopril for chronic therapy, it retains important niche indications: hypertensive urgency, heart failure initiation and titration (because its short half-life allows rapid dose adjustment), and the captopril challenge test for renovascular hypertension diagnosis. In China, captopril remains widely prescribed as a low-cost essential medicine. The API market is substantial, estimated at USD 1-1.2 billion globally by 2026 with approximately 12-13% CAGR. China and India are the dominant API producers. KingWish supplies GMP-certified captopril meeting USP, EP, and CP standards.

Quality Specifications

Applications

• Hypertension management: First-line ACE inhibitor for essential hypertension. Monotherapy or combined with thiazide diuretics. Rapid onset useful for hypertensive urgencies.
• Congestive heart failure: Reduces afterload, preload, and improves survival in CHF patients. Cornerstone of HFrEF therapy alongside beta-blockers and diuretics.
• Post-myocardial infarction therapy: ACE inhibitor initiated early post-MI reduces ventricular remodeling, infarct expansion, and long-term cardiovascular mortality.
• Diabetic nephropathy prevention: ACE inhibition reduces proteinuria and slows progression to end-stage renal disease in diabetic patients with microalbuminuria.